TNFRSF9 and neoplasm: EU101, a humanized IgG1 CD137 mAb, in Phase I/II clinical trials now, has strong anti‐tumor efficacy at high doses of 10 mg·kg−1 in the preclinical HT29 tumor model as an individual treatment.